VAQTA SUMMARY
VAQTA [Hepatitis A Vaccine, Inactivated] is an inactivated whole virus vaccine derived from hepatitis A virus (HAV) grown in cell culture in human MRC-5 diploid fibroblasts. It contains inactivated virus of a strain which was originally derived by further serial passage of a proven attenuated strain. The virus is grown, harvested, purified by a combination of physical and high performance liquid chromatographic techniques developed at the Merck Research Laboratories, formalin inactivated, and then adsorbed onto amorphous aluminum hydroxyphosphate sulfate. One milliliter of the vaccine contains approximately 50 units (U) of hepatitis A virus antigen, which is purified and formulated without a preservative. Within the limits of current assay variability, the 50U dose of VAQTA contains less than 0.1 mcg of a non-viral protein, less than 4 × 10-6 mcg of DNA, less than 10-4 mcg of bovine albumin, and less than 0.8 mcg of formaldehyde. Other process chemical residuals are less than 10 parts per billion (ppb).
VAQTA is indicated for active pre-exposure prophylaxis against disease caused by hepatitis A virus in persons 2 years of age and older. Primary immunization should be given at least 2 weeks prior to expected exposure to HAV.
|
VAQTA NEWS HIGHLIGHTS
Media Articles Related to Vaqta (Hepatitis A Vaccine)
Hepatitis A Vaccine Best Bet to Treat Virus
Source: MedicineNet Hepatitis Immunizations Specialty [2007.10.19]
Published Studies Related to Vaqta (Hepatitis A Vaccine)
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. [2008.05]
Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. [2008.05]
Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial. [2008.04.24]
Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. [2008.03.25]
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. [2008.03.04]
Clinical Trials Related to Vaqta (Hepatitis A Vaccine)
Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella [Oka/Merck] Virus Vaccine Live Safety Study [Completed]
Phase III, Open, Comparative Study in Healthy Adults Aged 18-50 Years Administered With Hepatyrix or Havrix + Typherix or Tiphim Vi, to Compare Reactogenicity and Immunogenicity. [Active, not recruiting]
Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age [Completed]
Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella, and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month Old Children [Active, not recruiting]
Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Measles/Mumps/Rubella Vaccine & a Varicella (Chickenpox) Vaccine in Healthy Children [Active, not recruiting]
|
